IL110852A - Methods of prolonged suppression of humoral activity - Google Patents

Methods of prolonged suppression of humoral activity

Info

Publication number
IL110852A
IL110852A IL11085294A IL11085294A IL110852A IL 110852 A IL110852 A IL 110852A IL 11085294 A IL11085294 A IL 11085294A IL 11085294 A IL11085294 A IL 11085294A IL 110852 A IL110852 A IL 110852A
Authority
IL
Israel
Prior art keywords
methods
antagonist
prolonged suppression
suppression
prolonged
Prior art date
Application number
IL11085294A
Other languages
English (en)
Other versions
IL110852A0 (en
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL110852(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of IL110852A0 publication Critical patent/IL110852A0/xx
Publication of IL110852A publication Critical patent/IL110852A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL11085294A 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral activity IL110852A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (2)

Publication Number Publication Date
IL110852A0 IL110852A0 (en) 1994-11-28
IL110852A true IL110852A (en) 1999-05-09

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11085294A IL110852A (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral activity

Country Status (14)

Country Link
EP (1) EP0742721B1 (xx)
JP (1) JP2840131B2 (xx)
CN (1) CN1137726C (xx)
AT (1) ATE179616T1 (xx)
AU (3) AU7643094A (xx)
DE (1) DE69418349T2 (xx)
DK (1) DK0742721T3 (xx)
ES (1) ES2134954T3 (xx)
FI (1) FI106927B (xx)
GR (1) GR3030762T3 (xx)
IL (1) IL110852A (xx)
NO (1) NO321037B1 (xx)
NZ (1) NZ273208A (xx)
WO (1) WO1995006480A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (en) * 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU655349B2 (en) * 1992-02-17 1994-12-15 Kenji Nakamura An antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
DE69418349D1 (de) 1999-06-10
JP2840131B2 (ja) 1998-12-24
FI960979A (fi) 1996-04-30
NO321037B1 (no) 2006-03-06
EP0742721A1 (en) 1996-11-20
AU734853B2 (en) 2001-06-21
NZ273208A (en) 2000-12-22
NO960863D0 (no) 1996-03-01
FI960979A0 (fi) 1996-03-01
DK0742721T3 (da) 1999-11-01
JPH09502184A (ja) 1997-03-04
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
AU7643094A (en) 1995-03-22
AU2004240180B2 (en) 2007-08-09
ES2134954T3 (es) 1999-10-16
IL110852A0 (en) 1994-11-28
FI106927B (fi) 2001-05-15
CN1137726C (zh) 2004-02-11
AU1422099A (en) 1999-04-01
ATE179616T1 (de) 1999-05-15
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
IL110852A (en) Methods of prolonged suppression of humoral activity
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
EP0777490A4 (en) ENTEROTOXIN MUTANT EFFECTIVE AS A NON-TOXIC ORAL ADJUVANT
DE122010000016I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
EP0863913A4 (en) METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS
EP0189915A3 (en) Reclining chair
NZ227812A (en) A medicament useful in reducing an immunoglobulin e response comprising as active ingredient as antagonist to human interleukin-4; and method of use
AU5888780A (en) Furniture glide and modular seating
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
ES8800273A1 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
吴玉章 et al. A new approach for B-cell epitope prediction in viral proteins
AU6136694A (en) Methods for generating broadly neutralizing anti-hiv antibodies and antigens capable of eliciting same
AT385191B (de) Sitz- und liegemoebel
ATA401983A (de) Sitz- und liegemoebel
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
GB8825395D0 (en) Furniture & method of upholstering same
ATA71792A (de) Sitz- und liegemöbel
AU7981287A (en) Reclining chair
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
ATA28490A (de) Sitz- und liegemoebel
郑需要 et al. 3-D seismic tomography for velocity and interface structure of the crust and upper mantle (theoreticalpart)
AU7423987A (en) Portable baby chair
Lindberg et al. Cell-mediated immune reactivity against Salmonella antigens in enteric infection.
AU2214788A (en) Chair seat construction

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired